Speaker Profile
Biography
Thomas Fuchs, Dr.sc., has served on the Board of Directors at GeneDx since September 2025. As the SVP and Chief AI Officer at Eli Lilly, Dr. Fuchs provides vision, strategic direction, and overall leadership of AI initiatives for drug discovery, clinical trials, manufacturing, commercial activities, and internal functions. He also identifies, builds and manages AI and machine learning solutions to help Lilly deliver medicines to patients around the world. Before joining Lilly, he was the Dean and inaugural Department Chair for AI and Human Health at Mount Sinai, Director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the endowed Barbara T. Murphy Professor for AI and Computational Pathology at the Icahn School of Medicine at Mount Sinai. Prior to Mount Sinai Dr. Fuchs held positions at Memorial Sloan Kettering Cancer Center, NASAs Jet Propulsion Laboratory and the California Institute of Technology and founded three companies, including Paige AI. Dr. Fuchs holds a doctoral degree in machine learning from ETH Zurich and a masters in technical mathematics from Graz Technical University in Austria.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
- William Oh, Yale Cancer Center
- David Reese, Amgen
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
PMWC Award Ceremony Honorees
• Nigam Shah, Stanford
Keynote
• David Reese, Amgen
Keynote
• Zachary Ziegler, OpenEvidence
Real-World Evidence & Clinical AI: Closing the Loop Between Data and Care
• Chair: Roxana Daneshjou, Stanford
• Aashima Gupta, Google
• David Sontag, Layer Health
• Brigham Hyde, Atropos Health
• Brian Bradbury, Amgen
From Data to Decisions: Building Regulatory-Grade RWE from EHR Systems in Oncology
• Chair: Kate Estep, Flatiron Health
AI for Clinical Decision Support: From Models to Bedside
• Chair: Amrita Basu, UCSF
• Anurang Revri, Stanford
• Emily Alsentzer, Stanford
• Okan Ekinci, Roche
Operationalizing AI in Health Systems: Trust, Adoption & Outcomes
• Chair: Danton Samuel Char, Stanford
• Matthew Solomon, Sutter Health
• Karan Singhal, Head of Health, OpenAI
• Sina Bari, iMerit Technology
• Hal Paz, Khosla Ventures
Safe, Scalable AI in Clinical Practice: What’s Working and What’s Not
• David Entwistle, CEO, Stanford Health Care
Workflow-First Clinical AI: Integration Patterns, Guardrails & Change Management
• Jorge Duran, Klick Health
From Patient-Generated Data to Regulatory-Grade RWE: Design, Bias & Outcome Linkage
• Greg Bowyer, Evidation




